NPI: 1104014703 · LOUISA, VA 23093 · Federally Qualified Health Center (FQHC) · NPI assigned 10/09/2007
Authorized official ALLBAUGH, CHARLES controls 18+ related entities in our dataset. Read more
| Authorized Official | ALLBAUGH, CHARLES (CFO) |
| NPI Enumeration Date | 10/09/2007 |
Other providers sharing the same authorized official: ALLBAUGH, CHARLES
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 1,296 | $60K |
| 2019 | 1,926 | $95K |
| 2020 | 2,024 | $97K |
| 2021 | 2,832 | $114K |
| 2022 | 4,868 | $108K |
| 2023 | 8,297 | $119K |
| 2024 | 4,705 | $56K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 99213 | Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 6,660 | 5,729 | $347K |
| 99214 | Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 3,348 | 3,083 | $218K |
| G0467 | Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit | 867 | 700 | $16K |
| 1159F | 2,990 | 2,657 | $10K | |
| 1160F | 2,982 | 2,651 | $10K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 244 | 224 | $7K |
| 3008F | 1,688 | 1,464 | $5K | |
| 3074F | 1,027 | 933 | $5K | |
| 1126F | 1,686 | 1,532 | $5K | |
| 3078F | 748 | 687 | $3K | |
| 90686 | 333 | 314 | $3K | |
| 99203 | Office or other outpatient visit for the evaluation and management of a new patient, low complexity | 54 | 41 | $3K |
| 1125F | 859 | 775 | $3K | |
| 83036 | Hemoglobin; glycosylated (A1C) | 635 | 590 | $3K |
| 3079F | 339 | 299 | $2K | |
| 0011A | 57 | 53 | $2K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 50 | 44 | $1K |
| 96127 | 310 | 286 | $1K | |
| 0012A | 36 | 35 | $1K | |
| 87428 | 44 | 43 | $618.80 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 37 | 36 | $442.77 |
| 3075F | 96 | 87 | $400.00 | |
| 81003 | 427 | 398 | $343.49 | |
| 99406 | 32 | 29 | $294.57 | |
| 0064A | 13 | 12 | $240.00 | |
| 4000F | 74 | 69 | $175.00 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 40 | 39 | $166.32 |
| 3077F | 41 | 37 | $150.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 12 | 12 | $57.60 |
| 80305 | 16 | 12 | $37.80 | |
| 3044F | 74 | 68 | $30.00 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 101 | 83 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 28 | 27 | $0.00 |